Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its target price hoisted by JPMorgan Chase & Co. from $165.00 to $167.00 in a research report sent to investors on Wednesday,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.
A number of other research analysts have also recently weighed in on the company. Stifel Nicolaus lifted their target price on Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a report on Friday, November 15th. UBS Group began coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price objective on the stock. Oppenheimer dropped their target price on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research report on Friday, November 15th. TD Cowen dropped their price objective on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Finally, StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $191.57.
Get Our Latest Report on Ascendis Pharma A/S
Ascendis Pharma A/S Stock Down 1.4 %
Institutional Investors Weigh In On Ascendis Pharma A/S
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Westfield Capital Management Co. LP grew its position in shares of Ascendis Pharma A/S by 3.4% during the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock worth $766,523,000 after buying an additional 170,942 shares in the last quarter. Janus Henderson Group PLC boosted its stake in Ascendis Pharma A/S by 6.8% during the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after acquiring an additional 267,881 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Ascendis Pharma A/S by 9.1% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock worth $278,760,000 after acquiring an additional 155,971 shares in the last quarter. Groupama Asset Managment bought a new stake in shares of Ascendis Pharma A/S in the 3rd quarter worth about $60,000. Finally, ARS Investment Partners LLC raised its stake in shares of Ascendis Pharma A/S by 0.9% in the 4th quarter. ARS Investment Partners LLC now owns 265,480 shares of the biotechnology company’s stock valued at $36,549,000 after purchasing an additional 2,369 shares in the last quarter.
About Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Further Reading
- Five stocks we like better than Ascendis Pharma A/S
- 3 Warren Buffett Stocks to Buy Now
- Coinbase Gains Momentum on App Store—What It Means for the Stock
- Where Do I Find 52-Week Highs and Lows?
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- Technology Stocks Explained: Here’s What to Know About Tech
- 3 Steel Stocks Soaring After Tariff Announcements
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.